Gene Page:FBXO5
Summary?
| GeneID | 26271 |
| Symbol | FBXO5 |
| Synonyms | EMI1|FBX5|Fbxo31 |
| Description | F-box protein 5 |
| Reference | MIM:606013|HGNC:HGNC:13584|Ensembl:ENSG00000112029|HPRD: 09348|Vega:OTTHUMG00000015854 |
| Gene type | protein-coding |
| Map location | 6q25.2 |
| Pascal p-value | 0.161 |
| Sherlock p-value | 0.529 |
基因数据urces
| Gene set name | Method of gene set | Description | Info |
|---|---|---|---|
| CV:GWASdb | Genome-wide Association Studies | GWASdb records for schizophrenia | |
| CV:PGCnp | Genome-wide Association Study | GWAS |
Section I. Genetics and epigenetics annotation
Section II. Transcriptome annotation
General gene expression (GTEx)
Gene expression of temporal and spatial changes (BrainSpan)
Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
死神:胎儿(13 - 26页ostconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes the lower 25% and upper 25% of the expression distribution.
Top co-expressed genes in brain regions
| Top 10 positively co-expressed genes | ||
| Gene | Pearson's Correlation | Spearman's Correlation |
| PLAGL2 | 0.92 | 0.88 |
| ZFYVE26 | 0.92 | 0.92 |
| PHF8 | 0.92 | 0.93 |
| KIAA1310 | 0.91 | 0.92 |
| ABL1 | 0.91 | 0.90 |
| BAZ2A | 0.91 | 0.94 |
| CCND2 | 0.91 | 0.90 |
| MAML1 | 0.91 | 0.89 |
| GCN1L1 | 0.91 | 0.89 |
| EP400 | 0.91 | 0.92 |
| Top 10 negatively co-expressed genes | ||
| Gene | Pearson's Correlation | Spearman's Correlation |
| AF347015.31 | -0.61 | -0.75 |
| AF347015.21 | -0.60 | -0.82 |
| MT-CO2 | -0.60 | -0.74 |
| IFI27 | -0.59 | -0.72 |
| FXYD1 | -0.58 | -0.71 |
| AF347015.27 | -0.58 | -0.70 |
| HIGD1B | -0.58 | -0.73 |
| AF347015.8 | -0.57 | -0.70 |
| C1orf54 | -0.56 | -0.80 |
| S100A16 | -0.56 | -0.69 |
Section III. Gene Ontology annotation
| Molecular function | 去的术语 | Evidence | Neuro keywords | PubMed ID |
|---|---|---|---|---|
| GO:0005515 | protein binding | 新闻学会 | 11988738|12791267 | |
| GO:0008270 | zinc ion binding | IEA | - | |
| GO:0046872 | metal ion binding | IEA | - | |
| Biological process | 去的术语 | Evidence | Neuro keywords | PubMed ID |
| GO:0000089 | mitotic metaphase | IEA | - | |
| GO:0001556 | oocyte maturation | IEA | - | |
| GO:0006511 | ubiquitin-dependent protein catabolic process | IEA | - | |
| GO:0016050 | vesicle organization | IEA | - | |
| GO:0007346 | regulation of mitotic cell cycle | IEA | - | |
| GO:0007346 | regulation of mitotic cell cycle | ISS | - | |
| GO:0007049 | cell cycle | IEA | - | |
| GO:0007057 | spindle assembly involved in female meiosis I | IEA | - | |
| GO:0007067 | mitosis | IEA | - | |
| GO:0007128 | meiotic prophase I | IEA | - | |
| GO:0051225 | spindle assembly | IEA | - | |
| GO:0051301 | cell division | IEA | - | |
| GO:0040020 | regulation of meiosis | IEA | - | |
| GO:0046785 | microtubule polymerization | IEA | - | |
| GO:0051436 | negative regulation of ubiquitin-protein ligase activity during mitotic cell cycle | IDA | 11988738|16921029 | |
| GO:0051437 | positive regulation of ubiquitin-protein ligase activity during mitotic cell cycle | EXP | 12791267 | |
| GO:0051442 | negative regulation of ubiquitin-protein ligase activity during meiotic cell cycle | IEA | - | |
| Cellular component | 去的术语 | Evidence | Neuro keywords | PubMed ID |
| GO:0005819 | spindle | IDA | 15469984 | |
| GO:0005829 | cytosol | EXP | 15469984 | |
| GO:0005634 | nucleus | IDA | 11988738 | |
| GO:0005654 | nucleoplasm | EXP | 11988738|12791267|15148369 |15469984 |
|
| GO:0005737 | cytoplasm | IDA | 11988738 | |
| GO:0005737 | cytoplasm | IEA | - |
Section V. Pathway annotation
| Pathway name | Pathway size | # SZGR 2.0 genes in pathway | Info |
|---|---|---|---|
| KEGG OOCYTE MEIOSIS | 114 | 79 | 所有SZGR 2.0基因通路 |
| PID PLK1 PATHWAY | 46 | 25 | 所有SZGR 2.0基因通路 |
| REACTOME CELL CYCLE | 421 | 253 | 所有SZGR 2.0基因通路 |
| REACTOME CELL CYCLE MITOTIC | 325 | 185 | 所有SZGR 2.0基因通路 |
| REACTOME G1 S TRANSITION | 112 | 63 | 所有SZGR 2.0基因通路 |
| REACTOME MITOTIC G1 G1 S PHASES | 137 | 79 | 所有SZGR 2.0基因通路 |
| REACTOME REGULATION OF MITOTIC CELL CYCLE | 85 | 46 | 所有SZGR 2.0基因通路 |
| REACTOME MITOTIC M M G1 PHASES | 172 | 98 | 所有SZGR 2.0基因通路 |
| REACTOME DNA REPLICATION | 192 | 110 | 所有SZGR 2.0基因通路 |
| REACTOME E2F MEDIATED REGULATION OF DNA REPLICATION | 35 | 17 | 所有SZGR 2.0基因通路 |
| REACTOME SCF BETA TRCP MEDIATED DEGRADATION OF EMI1 | 51 | 32 | 所有SZGR 2.0基因通路 |
| REACTOME G1 S SPECIFIC TRANSCRIPTION | 19 | 9 | 所有SZGR 2.0基因通路 |
| SOTIRIOU BREAST CANCER GRADE 1 VS 3 UP | 151 | 84 | 所有SZGR 2.0基因通路 |
| GARY CD5 TARGETS DN | 431 | 263 | 所有SZGR 2.0基因通路 |
| ODONNELL TFRC TARGETS DN | 139 | 76 | 所有SZGR 2.0基因通路 |
| TIEN INTESTINE PROBIOTICS 24HR UP | 557 | 331 | 所有SZGR 2.0基因通路 |
| KINSEY TARGETS OF EWSR1 FLII FUSION UP | 1278 | 748 | 所有SZGR 2.0基因通路 |
| SCIBETTA KDM5B TARGETS DN | 81 | 55 | 所有SZGR 2.0基因通路 |
| GRAHAM CML DIVIDING VS NORMAL QUIESCENT UP | 181 | 101 | 所有SZGR 2.0基因通路 |
| DODD NASOPHARYNGEAL CARCINOMA DN | 1375 | 806 | 所有SZGR 2.0基因通路 |
| RODRIGUES THYROID CARCINOMA POORLY DIFFERENTIATED UP | 633 | 376 | 所有SZGR 2.0基因通路 |
| TANG SENESCENCE TP53 TARGETS DN | 57 | 33 | 所有SZGR 2.0基因通路 |
| KAN RESPONSE TO ARSENIC TRIOXIDE | 123 | 80 | 所有SZGR 2.0基因通路 |
| ROSTY CERVICAL CANCER PROLIFERATION CLUSTER | 140 | 73 | 所有SZGR 2.0基因通路 |
| HERNANDEZ MITOTIC ARREST BY DOCETAXEL 1 DN | 38 | 23 | 所有SZGR 2.0基因通路 |
| NUYTTEN NIPP1 TARGETS DN | 848 | 527 | 所有SZGR 2.0基因通路 |
| BUYTAERT PHOTODYNAMIC THERAPY STRESS DN | 637 | 377 | 所有SZGR 2.0基因通路 |
| BENPORATH MYC MAX TARGETS | 775 | 494 | 所有SZGR 2.0基因通路 |
| GEORGES TARGETS OF MIR192 AND MIR215 | 893 | 528 | 所有SZGR 2.0基因通路 |
| STEGMEIER PRE-MITOTIC CELL CYCLE REGULATORS | 11 | 8 | 所有SZGR 2.0基因通路 |
| SHEPARD BMYB MORPHOLINO DN | 200 | 112 | 所有SZGR 2.0基因通路 |
| SHEPARD BMYB TARGETS | 74 | 41 | 所有SZGR 2.0基因通路 |
| SHEPARD CRUSH AND BURN MUTANT DN | 185 | 111 | 所有SZGR 2.0基因通路 |
| MANALO HYPOXIA DN | 289 | 166 | 所有SZGR 2.0基因通路 |
| VANTVEER BREAST CANCER METASTASIS DN | 121 | 65 | 所有SZGR 2.0基因通路 |
| VERNELL RETINOBLASTOMA PATHWAY UP | 70 | 47 | 所有SZGR 2.0基因通路 |
| MARSON BOUND BY E2F4 UNSTIMULATED | 728 | 415 | 所有SZGR 2.0基因通路 |
| SARRIO EPITHELIAL MESENCHYMAL TRANSITION UP | 180 | 114 | 所有SZGR 2.0基因通路 |
| FUJII YBX1 TARGETS DN | 202 | 132 | 所有SZGR 2.0基因通路 |
| MITSIADES RESPONSE TO APLIDIN DN | 249 | 165 | 所有SZGR 2.0基因通路 |
| BLUM RESPONSE TO SALIRASIB DN | 342 | 220 | 所有SZGR 2.0基因通路 |
| SHEDDEN LUNG CANCER POOR SURVIVAL A6 | 456 | 285 | 所有SZGR 2.0基因通路 |
| COLINA TARGETS OF 4EBP1 AND 4EBP2 | 356 | 214 | 所有SZGR 2.0基因通路 |
| CHIANG LIVER CANCER SUBCLASS PROLIFERATION UP | 178 | 108 | 所有SZGR 2.0基因通路 |
| SAKAI CHRONIC HEPATITIS VS LIVER CANCER UP | 83 | 63 | 所有SZGR 2.0基因通路 |
| CAIRO HEPATOBLASTOMA CLASSES UP | 605 | 377 | 所有SZGR 2.0基因通路 |
| DANG BOUND BY MYC | 1103 | 714 | 所有SZGR 2.0基因通路 |
| MARTENS TRETINOIN RESPONSE DN | 841 | 431 | 所有SZGR 2.0基因通路 |
| DUTERTRE ESTRADIOL RESPONSE 24HR UP | 324 | 193 | 所有SZGR 2.0基因通路 |
| JOHNSTONE PARVB TARGETS 3 DN | 918 | 550 | 所有SZGR 2.0基因通路 |
| BRUINS UVC RESPONSE EARLY LATE | 317 | 190 | 所有SZGR 2.0基因通路 |
| FEVR CTNNB1 TARGETS DN | 553 | 343 | 所有SZGR 2.0基因通路 |
| GOBERT OLIGODENDROCYTE DIFFERENTIATION UP | 570 | 339 | 所有SZGR 2.0基因通路 |
| REICHERT MITOSIS LIN9 TARGETS | 28 | 17 | 所有SZGR 2.0基因通路 |
| ZHOU CELL CYCLE GENES IN IR RESPONSE 6HR | 85 | 49 | 所有SZGR 2.0基因通路 |
| ZHOU CELL CYCLE GENES IN IR RESPONSE 24HR | 128 | 73 | 所有SZGR 2.0基因通路 |